Groups
Company Size (Fulltime employees)
Partnering Objectives
Functionality
Headquartner in China
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Medtech Category
Medtech Development Stage
Index
Countries
Reset

Henry Xiong China

Sinovant Sciences (http://www.sinovant.com) is an innovative biopharmaceutical company based in Shanghai, Beijing and Hong Kong. Sinovant was founded by Chinese scientists and physicians, including Chinese “Returnees”. Sinovant is uniquely positioned to bring cutting-edge global medical innovation to China, and transformative Chinese medical innovation to the world.  

   

Sinovant has a diverse pipeline of 11 investigational products in development, among which 5 drug candidates are in phase III or beyond. Our products span over 6 therapeutic areas including oncology, infectious disease, urology / nephrology, gastrointestinal diseases, dermatology and rare diseases. 

Website:
http://www.sinovant.com
Partnering Objectives
Headquartner in China
Yes
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Sinovant
Senior BD Director 

Dr. Weihong Xu United States

Stanford Genome Technology Center
Website:
med.stanford.edu/sgtc
Company Size (Fulltime employees)
11-50
Partnering Objectives
Please specify your partnering goal
technology development partnership
Headquartner in China
No
Your Research Tool and Service name
genomics
SGTC
Director 

Wenfeng Xu United States

Innovative biologics for cancer and other patients' unmet needs
Website:
Hengenix.com
Company Size (Fulltime employees)
1001-5000
Year of foundation
2010
Partnering Objectives
Please specify your partnering goal
co-dev
Headquartner in China
Yes
Biotech/Pharma Category
Hengenix
VP Research 
Functionality
Research and Development

wenlian xu China

New drug development
Website:
GHtherapeutics.com
Partnering Objectives
Headquartner in China
Yes
Biotech/Pharma Category
GH Therapeutics
CEO 

Zheng Xu China

Leading Investment and security company in China
Website:
https://www.gtja.com/content/m/index.html
Partnering Objectives
Headquartner in China
Yes
Guotaijunan security
Director 

shuyang xu China

天士力
Website:
www.tasly.com
Partnering Objectives
Headquartner in China
Yes
Biotech/Pharma Category
tasly
bd manager 

Mr. Kenneth Xu China

Genova Inc., a bio-pharma company dedicated in the innovation of better protein-drugs for viral diseases, cancer and auto-immune diseases. Novaferon ，the first novel protein drug of Genova, shows antiviral efficacy on viral clearance in a proof of concept randomized clinical trial and approved by Healthcare Canada and PMDA of Japan entering into phase 3 multinational centers clinical trial in last December. We are right looking for strategic parthership with big pharma. Contact: ctxu@genova.cn

Website:
www.genova.cn
Company Size (Fulltime employees)
201-500
Year of foundation
2006
Partnering Objectives
Please specify your partnering goal
To work with a reputable pharmaceutical, or medical institute, or government agency, on scientific and business development of Novaferon as an antiviral drug for COVID-19. Cooperating specifically on organizing and managing international clinical trials, laboratory and animal studies for COVID-19. Licensing rights for COVID-19 applications of Novaferon in defined territories, further equity cooperation might be accordingly considered
Headquartner in China
Yes
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Genova Inc
Vice President & Corporate Secretary 
Functionality
Business Development

Dr. Chuanbo Xu United States

Liquid biopsy blood test for early detection of cancers
Website:
www.freenome.com
Company Size (Fulltime employees)
51-200
Partnering Objectives
Please specify your partnering goal
Exploring opportunities
Headquartner in China
No
Biotech/Pharma Category
Freenome, Inc.
Senior Director, Clinical Development 
Functionality
Management

Mrs. Shirley Xu China

Yonghua Capital is an institutional investor, with headquarter in Shanghai and portfolio overseas. We have invested in over 40 companies in healthcare field over past 5 years.
Website:
http://www.yonghuacapital.com.cn/
Partnering Objectives
Headquartner in China
Yes
Yonghua Capital
Executive Director 
Functionality
Investment

Mr. Evan Xu China

Genetron Holdings Limited (“Genetron Health” or the “Company”) (Nasdaq: GTH) is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The Company has developed a comprehensive oncology portfolio that covers the entire spectrum of cancer management, addressing needs and challenges from early screening, diagnosis and treatment recommendations, as well as continuous disease monitoring and care. Genetron Health also partners with global biopharmaceutical companies and offers customized services and products.
Website:
ir.genetronhealth.com
Company Size (Fulltime employees)
501-1000
Year of foundation
2015
Partnering Objectives
Please specify your partnering goal
N/A
Headquartner in China
Yes
Genetron Health
Chief Financial Officer 
Functionality
Management